Celldex Therapeutics, Inc. (CLDX) Shares Bought by
Post# of 23113
Posted On: 04/11/2016 6:26:15 PM
Celldex Therapeutics, Inc. (CLDX) Shares Bought by Nationwide Fund Advisors
Posted by Rick on Apr 11th, 2016 // No Comments
Celldex Therapeutics logoNationwide Fund Advisors raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 22.3% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 115,044 shares of the biopharmaceutical company’s stock after buying an additional 20,996 shares during the period. Nationwide Fund Advisors owned 0.12% of Celldex Therapeutics worth $1,804,000 at the end of the most recent reporting period.
Separately, Rhenman & Partners Asset Management boosted its position in shares of Celldex Therapeutics by 8.5% in the fourth quarter. Rhenman & Partners Asset Management now owns 320,000 shares of the biopharmaceutical company’s stock worth $5,018,000 after buying an additional 25,000 shares in the last quarter.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded down 5.57% on Monday, hitting $4.41. 1,332,455 shares of the company were exchanged. The firm’s market cap is $435.28 million. The stock has a 50 day moving average price of $4.91 and a 200 day moving average price of $10.86. Celldex Therapeutics, Inc. has a one year low of $2.96 and a one year high of $30.28.
Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.02. The firm earned $1.80 million during the quarter, compared to the consensus estimate of $0.80 million. During the same period in the previous year, the company posted ($0.36) EPS. The firm’s revenue for the quarter was up 21.1% on a year-over-year basis. On average, equities research analysts forecast that Celldex Therapeutics, Inc. will post ($1.33) EPS for the current fiscal year.
A number of equities analysts have issued reports on CLDX shares. Wedbush reissued an “outperform” rating and issued a $24.00 target price on shares of Celldex Therapeutics in a report on Thursday, February 25th. Guggenheim cut shares of Celldex Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, March 7th. HC Wainwright cut their target price on shares of Celldex Therapeutics from $25.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, March 8th. Zacks Investment Research cut shares of Celldex Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 4th. Finally, Brean Capital reissued a “buy” rating and issued a $24.00 target price on shares of Celldex Therapeutics in a report on Tuesday, March 8th. Seven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Celldex Therapeutics presently has an average rating of “Hold” and an average target price of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Posted by Rick on Apr 11th, 2016 // No Comments
Celldex Therapeutics logoNationwide Fund Advisors raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 22.3% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 115,044 shares of the biopharmaceutical company’s stock after buying an additional 20,996 shares during the period. Nationwide Fund Advisors owned 0.12% of Celldex Therapeutics worth $1,804,000 at the end of the most recent reporting period.
Separately, Rhenman & Partners Asset Management boosted its position in shares of Celldex Therapeutics by 8.5% in the fourth quarter. Rhenman & Partners Asset Management now owns 320,000 shares of the biopharmaceutical company’s stock worth $5,018,000 after buying an additional 25,000 shares in the last quarter.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded down 5.57% on Monday, hitting $4.41. 1,332,455 shares of the company were exchanged. The firm’s market cap is $435.28 million. The stock has a 50 day moving average price of $4.91 and a 200 day moving average price of $10.86. Celldex Therapeutics, Inc. has a one year low of $2.96 and a one year high of $30.28.
Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, February 25th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.02. The firm earned $1.80 million during the quarter, compared to the consensus estimate of $0.80 million. During the same period in the previous year, the company posted ($0.36) EPS. The firm’s revenue for the quarter was up 21.1% on a year-over-year basis. On average, equities research analysts forecast that Celldex Therapeutics, Inc. will post ($1.33) EPS for the current fiscal year.
A number of equities analysts have issued reports on CLDX shares. Wedbush reissued an “outperform” rating and issued a $24.00 target price on shares of Celldex Therapeutics in a report on Thursday, February 25th. Guggenheim cut shares of Celldex Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, March 7th. HC Wainwright cut their target price on shares of Celldex Therapeutics from $25.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, March 8th. Zacks Investment Research cut shares of Celldex Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 4th. Finally, Brean Capital reissued a “buy” rating and issued a $24.00 target price on shares of Celldex Therapeutics in a report on Tuesday, March 8th. Seven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Celldex Therapeutics presently has an average rating of “Hold” and an average target price of $20.00.
Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.
12 Month Chart for NASDAQ:CLDX
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'